|
KMID : 0939920220540020458
|
|
대한암학회지
2022 Volume.54 No. 2 p.458 ~ p.468
|
|
|
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non?Small Cell Lung Cancer
|
|
Shin Hyun-Seock
Choi Ju-Whan
Lee Jin-Hwan
Lee Sung-Yong
|
|
|
Abstract
|
|
|
Purpose: Histone deacetylase inhibitors (HDACis) are epigenetic regulators and used clinically for hematopoietic malignancies. Recently, HDACis have received attention as a factor that modulates the immune system. In this study, the role of histone deacetylase (HDAC) expression as a predictive marker in lung cancer patients who were treated with immune checkpoint inhibitors (ICIs) and the role of HDACi and ICI combination treatment in the mouse tumor model were analyzed.
Materials and Methods: The overall response rate (ORR) and progression-free survival (PFS) were analyzed by the expression of HDAC. In vitro assay, the mRNA and protein expression levels of cytokines and programmed death-ligand 1 (PD-L1) were analyzed after HDACi treatment. In vivo assay, TC-1 tumor-bearing mice were treated with HDACi and mouse programmed cell death 1 (PD-1) inhibitor.
Results: The HDAC6 low expression group showed high ORR and prolonged PFS. When the selective HDAC6 inhibitor was administered to the A549 cell line, the levels of interleukin-1β and interleukin-6 decreased and the expression of PD-L1 was reduced. Mice that received both the mouse PD-1 inhibitor and pan-HDACi had a smaller tumor size than that of the mice from the control group. Moreover, mice treated with the mouse PD-1 inhibitor and pan-HDACi generated greater numbers of E7-specific CD8+ T cells.
Conclusion: HDAC6 expression can predict the prognosis of non?small cell lung cancer patients who were treated with ICIs. Furthermore, co-treatment with HDACi and PD-1 inhibitor was shown to decrease the tumor growth rate and create a favorable tumor microenvironment for cytotoxic T lymphocytes in the TC-1 mouse model.
|
|
|
KEYWORD
|
|
|
Non-small-cell lung carcinoma, Histone deacetylase, Histone deacetylase inhibitor, Tumor microenvironment, Immune checkpoint inhibitor, Interleukin, Programmed cell death 1
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|